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Summary  139 
The early detection of relapse following primary surgery for non-small cell lung cancer and the 140 
characterization of emerging subclones seeding metastatic sites might offer new therapeutic 141 
approaches to limit tumor recurrence. The potential to non-invasively track tumor evolutionary 142 
dynamics in ctDNA of early-stage lung cancer is not established. Here we conduct a tumour-143 
specific phylogenetic approach to ctDNA profiling in the first 100 TRACERx (TRAcking non-144 
small cell lung Cancer Evolution through therapy (Rx)) study participants, including one 145 
patient co-recruited to the PEACE (Posthumous Evaluation of Advanced Cancer 146 
Environment) post-mortem study. We identify independent predictors of ctDNA release and 147 
perform tumor volume limit of detection analyses. Through blinded profiling of post-operative 148 
plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients 149 
destined to experience recurrence of their lung cancer. Finally, we show that phylogenetic 150 
ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastases, providing 151 
a new approach for ctDNA driven therapeutic studies 152 
 153 
 154 
Main text  155 
Lung cancer is the leading cause of cancer death1-2. Metastatic non-small cell lung cancer 156 
(NSCLC) cannot be cured with systemic chemotherapy, yet clinical studies have shown a 5% 157 
benefit of post-operative (adjuvant) chemotherapy on overall survival3. This modest survival 158 
benefit may reflect a vulnerability of low volume disease within the context of reduced intra-159 
tumor heterogeneity4. Circulating tumor DNA (ctDNA) detection in plasma following 160 
resection of breast5,6 and colorectal7 tumors has been shown to identify patients destined to 161 
relapse post-operatively in advance of established clinical parameters. Identifying, monitoring 162 
and genomically characterizing residual disease following primary lung cancer surgery may 163 
improve outcomes in the adjuvant setting. This would create a therapeutic setting where only 164 
patients destined to recur would receive treatment and where intervention could be directed to 165 
the evolving tumor subclone that is seeding metastatic recurrence.  166 
Here, we report a bespoke multiplex-PCR NGS approach to ctDNA profiling within the context 167 
of the prospective tumor evolutionary NSCLC TRACERx study. We address determinants of 168 
ctDNA detection in early-stage NSCLC and investigate the ability of ctDNA to identify and 169 
genomically characterize post-operative NSCLC relapse within a tumor phylogenetic 170 
framework.   171 
Phylogenetic ctDNA profiling 172 
The TRACERx study monitors the clonal evolution of NSCLC from diagnosis through to 173 
death8,9. Using multi-region exome sequencing (M-Seq) derived tumor phylogenetic trees 174 
developed through prospective analysis of a 100 patient TRACERx cohort, we conducted a 175 
phylogenetic approach to ctDNA profiling in early-stage NSCLC (Fig. 1). Bespoke multiplex-176 
PCR assay-panels were synthesised for each patient, targeting clonal and subclonal single 177 
nucleotide variants (SNVs) selected to track phylogenetic tumor branches in plasma (Fig. 1). 178 
SNV detection in plasma was established through a calling algorithm employing negative 179 
control samples (see Methods). Analytical validation of the multiplex-PCR NGS platform 180 
demonstrated a sensitivity of above 99% for the detection of SNVs at frequencies above 0.1% 181 
and the specificity of detecting a single SNV was 99.6% (Extended Data Fig. 1a). At least 182 
two SNVs were detected in ctDNA from early-stage NSCLCs analyzed in our published 183 
discovery cohort data10, demonstrating biological sensitivity of a two SNV threshold for 184 
ctDNA detection. Therefore, we prospectively selected a threshold of two detected SNVs for 185 
calling a sample ctDNA positive for validation within this study; to minimize type I error when 186 
testing up to 30 tumour-specific SNVs per time-point in a single patient (see Extended Data 187 
Fig. 1b for justification).  188 
Determinants of ctDNA detection in NSCLC  189 
We sought to identify clinicopathological determinants of ctDNA detection in early-stage 190 
NSCLC by profiling pre-operative plasma samples in 100 TRACERx patients. Samples from 191 
four patients could not be analyzed (see cohort design Extended Data Fig. 2a, patient 192 
characteristics Extended Table 1a-c, Supplementary Table 1). Individual assay-panels were 193 
designed to target a median of 18 SNVs (range 10 to 22) comprising a median of 11 clonal 194 
SNVs (range 2 to 20) and a median of 6 subclonal SNVs (range 0 to 16) per patient (Extended 195 
Data Fig. 2b,e).  196 
At least two SNVs were detected in ctDNA pre-operatively in 46 of 96 (48%) early-stage 197 
NSCLCs and a single SNV was detected in 12 additional cases (Fig. 2a). Centrally reviewed 198 
pathological data revealed that ctDNA detection was associated with histological subtype: 97% 199 
(30/31) of lung squamous cell carcinomas (LUSCs) and 71% (5 of 7) of other NSCLC subtypes 200 
were ctDNA positive, compared with 19% (11/58) of lung adenocarcinomas (LUADs) (Fig. 201 
2a). 94% (16 of 17) of stage I LUSCs were detected compared with 13% (5 of 39) of stage I 202 
LUADs (Extended Data Fig. 3a). Passive release of ctDNA into the circulation may be 203 
associated with necrosis11. As expected LUSCs were significantly more necrotic than LUADs12 204 
and ctDNA positive LUADs formed a sub-group of more necrotic tumors compared with 205 
ctDNA negative LUADs (Extended Data Fig. 3b). Necrosis, lymph node involvement, 206 
lymphovascular invasion, pathological tumor size, Ki67 labelling indices, non-207 
adenocarcinoma histology and total cell-free DNA input predicted ctDNA detection in 208 
univariable analyses (Extended Data Fig. 3c). Multivariable analysis revealed non-209 
adenocarcinoma histology, the presence of lympho-vascular invasion and high Ki67 210 
proliferation index as independent predictors of ctDNA detection (Extended Data Fig. 3c). 211 
Since FDG-avidity on positron emission tomography (PET) scans correlates with proliferative 212 
indices in early-stage NSCLC13,14, we investigated tumor PET FDG-avidity and ctDNA 213 
detection. PET FDG-avidity predicted ctDNA detection (area under curve = 0.84, P<0.001, 214 
n=92) (Extended Data Fig. 3d). Within LUADs, driver events in KRAS, EGFR or TP53 were 215 
not associated with ctDNA detection (Extended Data Fig. 3e).  216 
We analyzed the distribution of clonal and subclonal SNVs in ctDNA positive patients. Clonal 217 
SNVs were detected in all 46 ctDNA positive patients and a median of 94% (range 11% to 218 
100%) of clonal SNVs targeted by assay-panels were detected in the ctDNA of these patients. 219 
40 of 46 ctDNA positive patients had subclonal SNVs targeted by assay-panels and subclonal 220 
SNVs were detected in 27 (68%) of these patients. A median of 27% (range 0% to 91%) of 221 
subclonal SNVs within individual assay-panels were detected in ctDNA positive patients (Fig. 222 
2b). The mean plasma variant allele frequency (VAF) of clonal SNVs was higher than that of 223 
subclonal SNVs (Extended Data Fig. 4a, within patient comparison, Wilcoxon signed-rank 224 
test, P<0.001, n=27, Supplementary Table 2) supporting the use of clonal alterations as a 225 
more sensitive method of ctDNA detection than subclonal alterations10,15.  226 
In ctDNA positive patients, pathologic tumor size correlated with mean clonal plasma VAF 227 
(Spearman’s Rho = 0.405, P=0.005, n=46, Extended Data Fig. 4b). CT scan volumetric 228 
analyses were available in 38 of 46 ctDNA positive patients (see Extended Data Fig. 4c). 229 
Tumor volume correlated with mean clonal plasma VAF (Fig 3a, Spearman’s Rho = 0.61, 230 
P<0.001, n=38). A linear relationship between log- transformed volume and log- transformed 231 
mean clonal VAF values was observed (Fig. 3a). The line of best fit applied to the data was 232 
consistent with the line fitted to NSCLC volumetric data and ctDNA plasma VAFs reported in 233 
previously published work16 (Extended Data Fig. 4d). Linear modelling based on the 234 
TRACERx data predicted that a primary tumor burden of 10cm3 would result in a mean clonal 235 
plasma VAF of 0.1% (95% C.I. 0.05 to 0.17%) (Fig. 3b). Tumor purity was multiplied by 236 
tumor volume to control for stromal contamination to determine cancer cell volume 237 
corresponding to clonal plasma VAF (Extended Data Fig. 4e). On the assumption that 1cm3 238 
of pure tumor contains 9.4 x 107 cells17, a plasma VAF of 0.1% would correspond to a primary 239 
NSCLC malignant burden of 326 million cells (Fig 3b, Extended Data Fig. 4f). 240 
To investigate predictors of subclone detection, detected subclonal SNVs were mapped back 241 
to M-seq derived tumor phylogenetic trees. 35 of 57 (61%) shared subclones (identified in more 242 
than one tumor region through M-Seq analysis) were identified in ctDNA, compared with 26 243 
of 80 (33%) private subclones (detected in a single tumor region only) (Extended Data Fig 244 
4g). This suggested subclone volume influences subclonal ctDNA detection. Subclone volume 245 
was estimated based on mean regional subclone cancer cell fraction and cancer cell volume. 246 
Detected subclonal SNVs mapped to subclones with higher estimated volumes than subclones 247 
containing undetected SNVs (Fig. 3c) and subclone volume correlated with subclonal SNV 248 
plasma VAF (Fig. 3d).  249 
Detecting and characterizing NSCLC relapse 250 
The longitudinal phase of the study aimed to determine if ctDNA profiling with patient-specific 251 
assay panels could detect and characterize the branched subclone(s) seeding NSCLC relapse. 252 
Pre- and post-surgical plasma ctDNA profiling was performed blinded to relapse status in a 253 
sub-group of 24 patients (cohort characteristics, Extended Table 1d-e). This included relapse 254 
free patients who had been followed-up for a median of 775 days (range 688 to 945 days, n=10) 255 
and confirmed NSCLC relapse cases (n=14) (cohort design, Extended Data Fig. 2c). 256 
Additional PCR assays were added to panels in this phase of the study to attempt to improve 257 
ctDNA detection in LUADs, a median of 18.5 SNVs (range 12 to 20) were targeted by LUSC 258 
assay-panels and a median of 28 SNVs (range 25 to 30) were targeted by LUAD assay-panels 259 
(Extended Data Fig. 2d-e).  260 
Patients were followed up with three to six monthly clinical assessment and chest radiographs. 261 
At least 2 SNVs were detected in 13 of 14 (93%) patients with confirmed NSCLC relapse prior 262 
to, or at, clinical relapse (Fig 4a-g, Extended Data Fig. 5).  At least two SNVs were detected 263 
in 1 of 10 (10%) patients (CRUK0013) with no clinical evidence of NSCLC relapse (Fig. 4h, 264 
Extended Data Fig. 6). Excluding a single case where no post-operative plasma was taken 265 
prior to clinical relapse (CRUK0041), the median interval between ctDNA detection and 266 
NSCLC relapse confirmed on clinically indicated CT imaging (lead-time) was 70 days (range 267 
10 to 346 days). Four of 13 relapse cases exhibited lead-times of more than six months (Fig. 268 
4a-d).  In two cases ctDNA detection preceded CT imaging inconclusive for NSCLC relapse 269 
by 157 days (CRUK0004, Fig 4b) and 163 days (CRUK0045, Fig 4d). ctDNA profiling 270 
reflected adjuvant chemotherapy resistance - CRUK0080, CRUK0004 and CRUK0062 had 271 
detectable ctDNA in plasma within 30 days of surgery. The number of detectable SNVs 272 
increased in all three cases despite adjuvant chemotherapy, with disease recurring within 1 year 273 
of surgery (Fig. 4a-c). In contrast, CRUK0013 had 20 SNVs detectable in ctDNA 72 hours 274 
after surgery and 13 SNVs detectable prior to adjuvant chemotherapy; 51 days following 275 
completion of adjuvant treatment and at post-operative days 457 and 667 no SNVs were 276 
detectable and the patient remains relapse free 688 days post-surgery (Fig. 4h). ctDNA 277 
profiling detected intracerebral relapse; CRUK0029 had a PET scan performed 50 days prior 278 
to surgery demonstrating normal cerebral appearances. ctDNA remained detectable following 279 
surgery, 54 days post-operatively the patient was diagnosed with intracerebral metastasis, no 280 
extracranial disease was evident on CT imaging (Fig. 4e).  281 
We sought to resolve subclonal evolutionary-dynamics associated with NSCLC relapse. 282 
Subclonal SNVs displaying plasma VAFs similar to clonal SNVs from clusters confined to a 283 
single phylogenetic branch, were detected post-operatively in the ctDNA of four patients who 284 
suffered NSCLC relapse (CRUK0004, CRUK0063, CRUK0065 and CRUK0044) (Fig. 4b,f-285 
g, Extended Data Fig 5b). This suggested a relapse process dominated by one subclone 286 
represented in our assay-panel. The subclone implicated by ctDNA as driving the relapse in 287 
the case of CRUK0004 contained an ERRB2 (HER2) amplification event (>15 copies, triploid 288 
background), that may be targetable in NSCLC18 (Fig. 4b). Relapses involving subclones from 289 
more than one phylogenetic branch were evident in patients CRUK0080, CRUK0062 (Fig. 290 
4a,c) and CRUK0041 (Extended Data Fig 5c). 291 
Validation of phylogenetic characterization 292 
To validate subclonal ctDNA analyses, data acquired from sequencing metastatic tissue at 293 
recurrence was integrated with M-seq primary tumor data (for biopsy details, Supplementary 294 
Table 3). Patient CRUK0063 suffered para-vertebral relapse of their NSCLC. Post-operative 295 
ctDNA analysis revealed the detection of the same subclonal SNV (OR5D18) on four 296 
consecutive occasions over a 231-day period (Extended Data Fig. 7a). The OR5D18 SNV 297 
traced back to a subclonal cluster private to primary tumor region three (Fig. 5a). CT-guided 298 
biopsy tissue was acquired from the para-vertebral metastasis at post-operative day 467. Exome 299 
sequencing of relapse tissue revealed the subclonal cluster containing the OR5D18 SNV gave 300 
rise to the metastatic subclone (Fig. 5a), this supported ctDNA phylogenetic characterization 301 
of relapse. The para-vertebral biopsy contained 88 SNVs not called as present in the primary 302 
tumor including an ARID1A stop-gain driver SNV. Re-examination of primary tumor region 303 
M-Seq data with a lower SNV calling threshold revealed that 16 of 88 SNVs, including 304 
ARID1A, were detectable in primary tumor region three, compared to a maximum of 2 of 88 in 305 
other tumor regions (Extended Data Fig. 7b). These data suggest that ctDNA profiling can 306 
resolve the primary tumor region from which a low frequency metastatic subclone derives. 307 
CRUK0035 developed two liver and one adrenal metastases (Fig. 5b). Sequencing of the 308 
metastatic liver deposit revealed that only 109 of 149 SNVs classed as clonal in the primary 309 
tumor were detectable in the metastasis. This was suggestive of an ancestral branching event 310 
not resolved through primary M-seq analysis (Fig 5b). Post-operative ctDNA profiling 311 
identified clonal SNVs present in the liver metastasis biopsy but also revealed SNVs 312 
representing a subclone from the primary tumor (Extended Data Fig 7c). This subclone was 313 
not present in the metastatic liver deposit (Fig 5b). These data may reflect ctDNA identified 314 
from the non-biopsied metastases suggesting multiple metastatic events. CRUK0044 suffered 315 
a vertebral and right hilar relapse. Post-operatively the same subclonal SNV (OR10K1), was 316 
detected in ctDNA on two occasions 85 days apart (Extended Data Fig. 7d). This SNV was 317 
represented in a single subclone detected through sequencing hilar lymph-node metastatic 318 
tissue, supporting ctDNA findings (Fig. 5c). CRUK0041 suffered an intracerebral, hilar and 319 
subcarinal lymph node relapse. Four subclonal SNVs representing both branches of the tumor 320 
phylogenetic tree were detectable in ctDNA at relapse. Consistent with these data, sequencing 321 
of subcarinal metastatic tissue revealed the presence of subclonal SNVs mapping to both 322 
phylogenetic branches (Fig 5d, Extended Data Fig. 7e). Patient CRUK0013 had detectable 323 
ctDNA 3 and 38 days post-operatively. Following adjuvant chemoradiotherapy for lymph-node 324 
metastases identified in the pathological specimen, ctDNA levels became undetectable (Fig 325 
4h). Two involved lymph-nodes were sampled for exome analysis together with M-seq of the 326 
primary tumor. Four subclonal SNVs detected in ctDNA post-operatively mapped to an 327 
ancestral subclone (describing a subclone that existed during the tumor’s evolution) (Extended 328 
Data Fig. 7f). This ancestral subclone contained a KRAS amplification (>15 copies, triploid 329 
background) and was identified as present in primary tumor and sampled lymph-nodes by M-330 
Seq (Fig. 5e). These data provide phylogenetic characterization of post-operative residual 331 
disease that responded to adjuvant chemoradiotherapy (Fig. 4h). 332 
ctDNA profiling in the metastatic setting 333 
Patient CRUK0063 underwent examination through the PEACE post-mortem study 24 hours 334 
following death. M-Seq data from the six post-mortem tumor regions (para-aortic, para-335 
vertebral and lung metastases, day 857), the para-vertebral relapse biopsy (day 467) and five 336 
primary tumor regions (day 0) were combined to infer the phylogenetic structure of this 337 
patient’s NSCLC (Fig. 6a). All seven metastatic tumor regions arose from a single ancestral 338 
subclone represented by phylogenetic cluster 8. Six metastatic regions shared a later 339 
phylogenetic origin, cluster 12 (Fig. 6b). The single tumor region not containing phylogenetic 340 
cluster 12 was sampled from the para-aortic metastasis at autopsy and contained a private 341 
subclone represented by phylogenetic cluster 9 (Fig. 6b).  342 
We designed a bespoke ctDNA assay-panel to retrospectively track metastatic subclonal 343 
burden. 20 clonal SNVs and a median of 8 subclonal SNVs (range 4 to 15) in each of 9 344 
metastatic subclonal clusters were targeted by the assay-panel (Extended Data Fig. 8). Since 345 
103 variants per time-point were profiled, SNV detection thresholds were increased to maintain 346 
platform specificity (see Methods). This resulted in a predicted false positive rate (FPR) of 347 
0.0011 translating to a 10.7% risk of a single false-positive SNV at each time point and a 0.5% 348 
risk of 2 false-positive SNVs at each time point when testing 103 SNVs.  349 
Two clonal SNVs were detected by the 103 SNV assay-panel at day 151 post-surgery (Fig 6c, 350 
Extended Data Fig. 8), 189 days prior to the time point ctDNA was detected using the 19 SNV 351 
assay-panel in Figure 4f. At day 242 a single subclonal SNV was detected from phylogenetic 352 
cluster 8 (Fig 6c, Extended Data Fig. 8), within the context of a 10.7% false-positive risk a 353 
single SNV call could represent type I error. At day 466, following clinical-relapse at the 354 
thoracic para-vertebral site, 18 of 20 SNVs mapping to phylogenetic clusters (8,11 and 12) 355 
were detected in ctDNA, these subclonal clusters were shared between six of seven metastatic 356 
sites (Fig 6b-c, Extended Data Fig. 8). Single SNVs from two private subclones (phylogenetic 357 
cluster 5 and 9) were also detectable in ctDNA at day 466 (Fig 6c, Extended Data Fig. 8). 358 
These subclones were not identified in the CT guided para-vertebral biopsy taken at day 467 359 
(Fig. 6b). The mean plasma VAF of the SNVs detected in phylogenetic clusters 11, 8, 12, 9 360 
and 5 mirrored their proximity to the clonal cluster (light blue) in the M-Seq derived 361 
phylogenetic tree (Fig. 6a,c). This suggested a tiered burden of subclonal disease concordant 362 
with M-seq phylogenetic inferences. Mean clonal VAF fell in response to palliative 363 
radiotherapy and chemotherapy, but at day 767 increased (Fig. 6c). Single SNVs mapping to 364 
phylogenetic clusters 5 and 9 and two SNVs mapping to phylogenetic cluster 2 were now 365 
detectable in ctDNA 90 days before death (Fig. 6a-c, Extended Data Fig 8). These three 366 
phylogenetic clusters represented subclones private to the para-aortic metastases (Fig 6. a-b). 367 
Consistent with these data significant para-aortic progression was observed at post-mortem 368 
compared with most recent CT imaging performed 112 days before death - which showed no 369 
evidence of para-aortic disease. 370 
Discussion 371 
In summary, we find predictors of ctDNA detection in early-stage NSCLC characterized by 372 
non-adenocarcinoma histology, necrosis, increased proliferative indices and lymphovascular 373 
invasion. Triple negative breast cancers display necrosis19, high proliferative indices20,21 and 374 
are associated with increased ctDNA levels compared with other breast cancer subtypes6 375 
suggesting extension of these observations beyond NSCLC.  376 
Tumor volume correlated with plasma ctDNA VAF (Fig 3a.). A primary NSCLC tumor 377 
volume of 10cm3 predicted a ctDNA plasma VAF of 0.1%; the VAF conferring optimum 378 
sensitivity for most ctDNA platforms. Low-dose CT lung screening can identify lung nodules 379 
with diameters from 4mm22. Assuming a spherical nodule this would translate to a tumor 380 
volume of 0.034cm3. Based on the relationship between tumor volume and ctDNA plasma 381 
VAF observed in this study a tumor volume of 0.034cm3 would equate to a plasma VAF of 382 
1.4 x 10-4 % (95% CI, 6.4 x 10-6 to 0.0031%), at the extreme of detection limits of current 383 
ctDNA platforms23. Sensitivity of clonal SNV ctDNA directed early NSCLC screening may 384 
therefore be constrained by tumor size using current technologies.  385 
A limitation to targeted ctDNA profiling is cost, estimated at $1750 per patient for sequencing 386 
a single tumor region, synthesis of a patient-specific assay-panel and profiling of five plasma 387 
samples. Adjuvant platinum-based chemotherapy in NSCLC improves cure rates following 388 
surgery in only 5% of patients and 20% patients receiving chemotherapy experience acute 389 
toxicities3. There is a need to increase adjuvant therapy efficacy and better target its use. 390 
Bespoke ctDNA profiling can characterize the subclonal dynamics of relapsing NSCLC and 391 
identify adjuvant chemotherapy resistance. These findings indicate that drug development 392 
guided by ctDNA platforms to identify residual disease, define adjuvant treatment response 393 
and target emerging subclones prior to clinical recurrence in NSCLC, with appropriate CLIA 394 
validation, are now feasible. 395 
 396 
Supplementary information is available in the online version of the paper 397 
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Figure 1. Phylogenetic ctDNA tracking 499 
Overview of the study methodology. Multi-region sequencing of NSCLC was performed as 500 
part of the TRACERx study. PCR assay-panels were designed based on phylogenetic analysis, 501 
targeting clonal and subclonal single nucleotide variants to facilitate non-invasive tracking of 502 
the patient-specific tumor phylogeny. Assay-panels were combined into multiplex assay-pools 503 
containing primers from up to 10 patients. Cell-free DNA was extracted from pre- and post-504 
operative plasma samples and multiplex-PCR performed, followed by sequencing of 505 
amplicons. Findings were integrated with M-Seq exome data to track tumor evolution. 506 
Figure 2. Clinicopathological predictors of ctDNA detection 507 
a) Heatmap showing clinicopathological and ctDNA detection data, continuous variables 508 
quartiled. Raw data and patient IDs in attached worksheet. b) Detection of clonal and subclonal 509 
single nucleotide variants within 46 patients with two or more single nucleotide variants 510 
detected in plasma. Histology indicated in panels as LUSC, LUAD and Other.  511 
Figure 3. Tumor volume predicts plasma variant allele frequency 512 
a) Tumor volume (cm3) measured by CT volumetric analysis correlates with mean clonal 513 
plasma VAF, n=38, grey vertical lines represent range of clonal VAF, red shading indicates 514 
95% confidence intervals. b) Predicted mean clonal VAF at hypothetical volumes ranging from 515 
1 to 100cm3 based on model in panel a, predicted cancer cell number based on model in 516 
extended data 4e. c) Estimated effective subclone size, defined as mean CCF of subclone 517 
multiplied by tumor volume and purity, influences subclonal SNV detection. For negative calls, 518 
median effective subclone size was 1.70 cm3, range= 0.21-24.11, n=163, for positive calls, 519 
median effective subclone size = 4.06 cm3, range = 0.31 – 49.20, n=109. Wilcoxon rank sum 520 
test, P<0.001, data from 34 patients (passed volumetric filters with subclonal SNVs represented 521 
in assay-panel). d) Estimated effective subclone size correlates with subclonal plasma VAF, 522 
n=109 subclonal SNVs, data from 34 patients (passed volumetric filters with detected 523 
subclonal SNVs in plasma).  524 
Figure 4. Post-operative ctDNA detection predicts and characterizes NSCLC relapse   525 
a-h) Longitudinal cell-free DNA profiling. Circulating tumor DNA (ctDNA) detection in 526 
plasma was defined as the detection of two tumor-specific SNVs. Detected clonal (circles, light 527 
blue) and subclonal (triangles, colors indicates different subclones) SNVs from each patient-528 
specific assay-panel are plotted on graphs colored by M-Seq derived tumor phylogenetic nodes. 529 
Mean clonal (blue) and mean subclonal (red) plasma VAF are indicated on graphs as connected 530 
lines. Pre-operative and relapse M-Seq derived phylogenetic trees represented by ctDNA are 531 
illustrated above each graph. 532 
Figure 5. Phylogenetic trees incorporating relapse tissue sequencing data  533 
Phylogenetic trees based on mutations found in primary and metastatic tissue (a-d), or 534 
primary tumor and lymph node biopsies (e). Colored nodes in phylogenetic trees indicate 535 
cancer clones harboring mutations assayed for in ctDNA, grey indicates a clone not assayed. 536 
Branch length is proportional to number of mutations unless crossed. Dashed red lines show 537 
branches leading to metastatic relapse. Colored bars below show the number of assays per 538 
sample detected preoperatively and at relapse (a-d) or in the absence of relapse, post-surgery 539 
(e). Thin colored bar shows number of assays in total. Colors match clones on the 540 
phylogenetic trees. 541 
Figure 6. ctDNA tracking of lethal cancer subclones in CRUK0063 542 
Phylogenetic analysis of one relapse biopsy (day 467) and five metastatic biopsies (post 543 
mortem) a) To-scale phylogenetic tree of CRUK0063 including M-seq based on metastatic 544 
and primary tumor regions. Branch length is proportional to number of mutations in each 545 
subclone. b) Phylogenetic trees matching metastatic lesions, colored nodes represent 546 
mutation clusters found at each site and assayed for in ctDNA. Open circles represent 547 
mutation clusters not detected in ctDNA. c) Tracking plot showing mean VAF of identified 548 
mutation clusters in ctDNA. Size of dots indicates number of assays detected. Colors 549 
correspond to mutation clusters and match panels a) and b).  550 
Methods 551 
Patients and samples 552 
The cohort of 100 patients evaluated within this study comprises the first 100 patients 553 
prospectively analyzed by the lung TRACERx study (Clinicaltrials.gov no: NCT01888601, 554 
approved by an independent Research Ethics Committee, 13/LO/1546) and mirrors the 555 
prospective 100 patient cohort by Jamal-Hanjani M et al9. All surgically resected primary 556 
tumor samples were macroscopically reviewed by a pathologist. Spatially separated tumor 557 
regions, documented by photography, were collected and snap frozen in liquid nitrogen for 558 
subsequent DNA extraction. Relapse tissue samples, excess to diagnostic requirements, were 559 
acquired via clinical procedures including CT guided biopsy and endoscopic bronchial 560 
ultrasound guided biopsy. Fresh tissue for research was snap frozen immediately following 561 
acquisition for subsequent DNA extraction. Post mortem examination was performed through 562 
the PEACE study within 24 hours of death (Clinicaltrials.gov no: NCT03004755, approved by 563 
an independent Research Ethics Committee, 13/LO/0972). Details on relapse tissue sampling 564 
available in Supplementary Table 3. Informed consent was obtained from all subjects in this 565 
study. 566 
Tissue microarray creation and Ki67 immunohistochemistry 567 
Tissue microarrays (TMAs) were created of 100 NSCLC cases for Ki67+ 568 
immunohistochemistry.  Representative tumor areas were defined by examination of H&E 569 
stained sections from all 100 tissues blocks. From each NSCLC case two 2mm cores were 570 
selected from different regions within each specimen and re-embedded in recipient blocks, 571 
resulting in a TMA of 200 cores with four normal lung cores as negative control. 2-5μm 572 
sections from tissue-microarrays containing tumor were cut. Immunohistochemistry with anti-573 
Ki67 monoclonal antibody (Dilution 1:100; clone MIB-1; DAKO Agilent Technologies LDA, 574 
UK Limited, Stockport, Cheshire SK8 3GR, UK) was performed using BenchMark Ultra 575 
(Ventana/Roche). The percentage of Ki67 positive cells were averaged across two tumor 576 
sections for each case. Detection was performed using the peroxidase-based detection reagent 577 
conjugate (OptiView DAB IHC Detection Kit; Ventana Medical Systems, Inc).  578 
Central histopathological review 579 
Digital images of tumor sections from all cases were reviewed in detail centrally by at least 580 
one pathologist, and in cases of uncertainty, by two. Percentage of necrosis and the presence 581 
of lymphovascular invasion were all evaluated on digital images from scanned diagnostic slides 582 
blinded to the ctDNA detection status of the patient in question. 583 
Central radiology review & volume estimation 584 
92 of 96 anonymized diagnostic PET-CT were retrospectively reviewed by a Nuclear Medicine 585 
Physician, blinded to the initial PET-CT reports. Scan images were not available in three cases 586 
(CRUK0025, CRUK0039 and CRUK0023) and in one case a pre-operative PET-CT was not 587 
performed (CRUK0082). CT and PET images were matched and fused into transaxial, coronal 588 
and sagittal images and reviewed on a dedicated PET/CT software visualizer (AW 4.1/4.2 GE 589 
medical systems). The semi-quantitative parameter Standardized Uptake Value (SUV) max for 590 
the primary tumor mass was calculated and recorded along with SUVmax of mediastinal 591 
background uptake. Tumor-to-background ratio (TBR) was calculated based on SUVmax of the 592 
tumor divided by mediastinal background uptake24,25. Tumor volume was determined based on 593 
tumor CT scans. CT slices of the primary tumor were measured with 3D Slicer applying the 594 
“lung algorithm window” settings, tumor contours were segmented on each axial CT slice. 595 
These steps were performed by an experienced resident (W.L.B.), and all contours were 596 
confirmed and edited where necessary, by a radiologist with 14 years of experience in cancer 597 
imaging (F.M.F.). Effective tumor volume was defined as tumor volume multiplied with the 598 
mean purity of the tumor based on M-seq, purity estimates derived from ASCAT analysis as 599 
described9. Effective subclone size was defined as mean cancer cell fraction (CCF) across the 600 
regions of the mutation cluster multiplied by tumor volume and mean tumor purity. 601 
DNA extraction & quantification 602 
For cell-free DNA (cfDNA) extraction, blood samples were collected in K2 EDTA tubes. 603 
Samples were processed within 2 hours of collection by double spinning of blood first at 10 604 
minutes at 1000g then plasma 10 minutes at 2000g. Plasma was stored in 1ml aliquots at – 605 
80oC. Up to 5ml of plasma per case was available for this study (range 1-5ml, median 5 ml). 606 
The entire volume of plasma was used for cfDNA extraction. cfDNA was extracted using the 607 
QIAamp Circulating Nucleic Acid kit (Qiagen) and eluted into 50 µl DNA Suspension Buffer 608 
(Sigma). The purified cfDNA was stored at -20oC until use. Genomic DNA was extracted from 609 
each tumor region as described9. Every cfDNA sample was QCed and quantified on the 610 
Bioanalyzer High Sensitivity (Agilent) using a standard curve generated from pre-quantified 611 
mono-nucleosomal DNA samples. Plasma cfDNA consists of a main mono-nucleosomal peak 612 
(~160 bp); for some samples, di-nucleosomal and tri-nucleosomal peaks are visible (at ~320 613 
bp and ~500 bp, respectively). The library prep method used selectively amplifies the mono-614 
nucleosomal fraction of cfDNA. 615 
Exome sequencing and processing 616 
Whole exome sequencing was performed on DNA purified from tumor tissue and normal blood 617 
as described9, with the exception of CRUK0063_BR_T1-R1. This capture was performed 618 
according to the manufacturer’s 200 ng DNA protocol (Agilent). Annotated SNV calls are 619 
available in Supplementary Table 3 in Jamal-Hanjani et al. 20179.  For this study, one relapse 620 
sample was acquired through metastatic tissue biopsies from each of four patients (CRUK0035, 621 
CRUK0041, CRUK0044, CRUK0063). Additionally, six metastatic samples were acquired at 622 
post mortem examination of CRUK0063. Genomic DNA was purified from all tissue samples, 623 
and processed through the TRACERx bioinformatics pipeline as described9. Annotated SNV 624 
calls are available in Supplementary Table 5. 625 
SNV assay design 626 
The Natera assay design pipeline was used to generate forward and reverse PCR primers for 627 
all somatic SNVs detected in tumor samples. The assays were combined into pools such that 628 
any primer pair in a pool is not predicted to form primer dimers. In this way 10 balanced pools 629 
were created, each containing the assays for 10 patients’ SNVs. For each patient, assays were 630 
prioritized such that, 1) assays covering driver SNVs had highest priority, and 2) there was 631 
uniform sampling of phylogenetic tree. For the longitudinal cohort, up to 10 extra assays were 632 
generated for adenocarcinoma samples. SNV assays were ordered from IDT (Coralville, IA) 633 
as individual oligos in 96-well plates, desalted and normalized to 100 µM each. The oligos 634 
were pooled according to the pooling strategy previously described10 and each pool was QC-635 
ed by running the multiplex PCR and sequencing protocol using one plasma cfDNA library 636 
from a healthy subject. For each pool, the sequencing data was analyzed to determine the 637 
amount of primer-dimer reads and to identify drop-out assays. Primers contributing to dimer 638 
formation were removed from each final pool.  639 
Analytical validation 640 
Synthetic spikes representing twenty SNVs randomly selected from Pool 1 were designed and 641 
synthesized (IDT, Coralville, IA) as 160 bp oligos with the respective SNV placed in the middle 642 
(position 80). These synthetic spikes were mixed at equimolar ratios and used to prepare a 643 
library. This library was titrated into a library prepared from mono-nucleosomal DNA (10,000 644 
copies) from a normal cell line (AG16778 from Coriell, Camden, NJ). The library of 20 645 
synthetic spikes was titrated into the mononucleosomal DNA library at 2.5%, 0.5%, 0.25%, 646 
0.1%, 0.05% and 0% (each in triplicate), and 0.01%, 0.005% and 0.001% (each in 647 
quadruplicate. Because preparing spiked samples at such low levels is either subject to 648 
sampling noise (0.01% spikes into 10,000 genomic copies background is equivalent to one 649 
mutant copy), or is not possible (at levels less than 0.01%), samples were mixed as libraries. 650 
Following library mixing and sequencing, data was analyzed to detect all the targets in Pool 1 651 
using the same parameters as used for the patient samples. Targets that had a depth of read less 652 
than the threshold were not analyzed. The measured VAF of each spike for the samples with 653 
2.5% nominal input was used to calculate an input correction factor (measured VAF/2.5%); 654 
that was applied to the other inputs of the corresponding spike titration series. The measured 655 
VAF differed from the nominal input most likely because the mononucleosomal fragmentation 656 
pattern is not entirely random. Because of this, the actual input levels differ from the nominal 657 
input levels, and the sensitivity is measured based on corrected input intervals (chosen such 658 
that there are a meaningful number of samples in each interval). Sensitivity of >99% at SNV 659 
input frequencies down to 0.1% was achieved (199 SNVs detected out of 201 eligible positive 660 
positions), with a specificity of 99.6% for all negative SNV positions (19 false positive SNVs 661 
called out of 5099 eligible positions). 662 
Plasma SNV mPCR-NGS workflow 663 
Forty microliters of the extracted cfDNA from each case was used as input into library 664 
preparation using the Natera Library Prep Kit. All purified libraries were QC-ed on the 665 
LabChip GX 5k DNA chip. Successful libraries had a single peak at ~250 bp. The amplified 666 
libraries were then analyzed by mPCR-NGS. Optimal mPCR conditions were as described. 667 
Each PCR assay pool was used to amplify the SNV targets from the 10 corresponding samples 668 
and 20 negative control samples (plasma libraries prepared from healthy subjects). Each 669 
amplicon pool was sequenced on one Illumina HiSeq 2500 Rapid Run with 50 cycles paired-670 
end reads using the Illumina Paired End v1 kit with an average target DOR of ~40,000 per 671 
assay. 672 
Plasma SNV calling algorithm 673 
The set of SNVs covered by the assays in a pool were considered as target SNVs for the 674 
corresponding sequencing run. Target assays with <1000 reads in the plasma samples were 675 
considered failed and were not analyzed further. At each SNV position, an error model was 676 
built using all of the 20 negative control samples plus the cancer samples that were not expected 677 
to contain that particular SNV (based on tumor-tissue sequencing). Samples with high plasma 678 
VAF (>20%) among the putative negatives were considered to have possible germline mutation 679 
and were excluded from the error model. A confidence score was calculated for each target 680 
SNV based on the error model. A positive plasma SNV call was made if the confidence score 681 
for that mutation in the corresponding plasma sample passed our confidence threshold. The 682 
SNVs called positive in plasma samples that were not expected to contain the given SNVs were 683 
considered ‘false positive’, the false positive rate under these conditions was 0.24%. Notably, 684 
there was no difference in depth of read between called and not called SNVs (Extended Data 685 
Fig 1c). New assays were designed for CRUK0063 based on M-seq of metastatic biopsy 686 
retrieved at day 467 and of metastatic lesions harvested post mortem. A total of 103 assays 687 
were designed compared to 19 based on the primary tumor alone. An updated error threshold 688 
was designed to control for false positives by using the original threshold to make SNV calls 689 
on the negative samples in the run; the rate of calls were measured and defined as false-690 
positives. This false positive rate was then applied to the number of eligible positions in the 691 
positive samples. This was repeated with more stringent thresholds until the expected number 692 
of false positives in the eligible positions becomes ~1.  All multiplex PCR-NGS ctDNA SNV 693 
assays are available in Supplementary Table 6 (Baseline, pre-operative cohort assays), 694 
Supplementary Table 7 (Longitudinal Assays), and Supplementary Table 8 (Extended 695 
Longitudinal Assays for CRUK0063). 696 
Cross-platform validation using generic PCR-NGS panel section 697 
Cross-platform validation was performed in 28 patients with M-Seq confirmed SNV(s) within 698 
one or more hotspots targeted by a generic multiplex PCR-NGS panel (Extended Table 2a-b, 699 
Supplementary Table 9). 20ng of isolated cfDNA was used for library preparation using the 700 
Oncomine™ Lung cfDNA Assay (ThermoFisher Scientific), according to the manufacturer’s 701 
instructions. Automated template preparation and chip loading was conducted on the Ion 702 
Chef™ instrument using the Ion 520™ & Ion 530™ Kit-Chef (ThermoFisher Scientific). 703 
Ultimately, samples were sequenced on Ion 530™ chips using the Ion S5™ System 704 
(ThermoFisher Scientific). Sequencing data was accessed on the Torrent suite v5.2.2. Reads 705 
were aligned against the human genome (hg19) using Alignment v4.0-r77189, and variants 706 
were called using the coverage Analysis v4.0-r77897 plugin. All 18 bespoke-panel ctDNA 707 
negative patients had no tumor SNVs detectable in plasma pre-operatively by the generic panel 708 
supporting biological specificity of the bespoke targeted approach, 7 of 10 bespoke-panel 709 
ctDNA positive patients had tumor SNVs detected in plasma by the generic panel (Extended 710 
Table 2a-b). SNVs detected by hotspot panel not identified by M-Seq are displayed in Extended 711 
Table 2c. 712 
Processing and phylogenetic analysis of relapse and primary tumor multiregion 713 
whole exome data 714 
Biopsies from multiple regions from the primary tumor (n=327), metastatic biopsies (n=4) and 715 
matching blood germline samples (n=100) were subjected to multi-region whole exome 716 
sequencing and analysis including estimation of copy number, purity and ploidy, and 717 
phylogenetic tree construction as described9. Briefly, phylogenetic analysis was performed 718 
based on CCF determined for SNVs and clustered across tumor regions using a modified 719 
version of Pyclone9 into clusters with similar CCF values, filtered and processed as described9. 720 
Mutation clusters are assumed to represent tumor subclones, either current or ancestral, and are 721 
used as input for construction of phylogenetic relationship. Phylogenetic trees were primarily 722 
constructed using the published tool CITUP (0.1.0)26. However, in a small number of cases, 723 
including all relapse/autopsy cases, manual tree construction was required and performed as 724 
described9. Complete detail of primary tumor tree construction can be found in Jamal-Hanjani 725 
et al. 20179. Relapse tree construction was performed as follow: CRUK0063: clustering was 726 
performed twice, once across 5 primary tumor regions and once across 5 primary, 1 relapse, 727 
and 6 autopsy regions. To ensure consistency, when deriving a phylogenetic tree based on all 728 
tumor regions, CCF clusters based on clustering only the primary tumor regions were 729 
maintained for mutations not involved in metastatic relapse. A phylogenetic tree was 730 
constructed based on 17 mutation clusters. CRUK0035: Clustering primary tumor regions with 731 
the relapse region revealed one cluster private to the relapse, and one cluster shared with the 732 
relapse and all other regions. CRUK0044: Clustering primary tumor regions with the relapse 733 
region revealed a cluster private to the relapse, descended from a cluster private to region 1 in 734 
the primary tumor. CRUK0041: Clustering primary tumor regions with the relapse region 735 
revealed cluster 4 as private to the relapse. This cluster must have evolved from cluster 3 only 736 
found in the relapse and in region 4. A private cluster 6 in region 4 must have evolved from 737 
cluster 4. However, this conflicts with clusters 2 and 5, found in the relapse and regions 1-3, 738 
but not region 4. This can be reconciled by assuming a polyclonal relapse, seeded primarily 739 
from regions 1-3, but with some contribution from cluster 3, private to region 4. Cluster data 740 
is available in Supplementary Table 5 under “PyClonePhyloCluster”.  741 
Statistical data analysis 742 
Analysis was performed in the R statistical environment version 3.2.3 and SPSS version 24. 743 
All statistical tests were two-sided unless expressly stated. Multivariate logistic regression used 744 
detection of ctDNA (the dependent variable) classified as detection of 2 or more patient-745 
specific variants in ctDNA and the covariates listed in Supplementary Table 1. All predictors 746 
were entered simultaneously into the regression. All continuous independent variables were 747 
found to be linearly related to the logit of the dependent variable (assessed via the Box-Tidwell 748 
procedure). The logistic regression model was statistically significant, X2(10) = 81.35, P<0.001 749 
and the Hosmer-Lemeshow P value was 0.9858 indicating that the model was not a poor fit. 750 
To determine the ability of PET TBR to predict whether or not tumor ctDNA was identified in 751 
plasma, PET TBR estimates were analyzed by ROC curve analysis against binary detection of 752 
ctDNA in plasma at baseline based on at least two variants detected, significance test based on 753 
Wilcoxon rank sum test. For analysis involving longitudinally detected variants (Figure 4, 754 
Extended Figure 5), only subclonal variants from pyclone clusters present in phylogenetic trees 755 
were displayed, this did not affect ctDNA detection status of any time-points. In non-relapse 756 
cases presented in Extended Data Fig 6 all detected subclonal SNVs were plotted. To determine 757 
the relationship between tumor volume and ctDNA VAF, ctDNA assays against clonal SNVs 758 
were selected. For each patient, the mean ctDNA VAF of the clonal SNVs was determined as 759 
baseline for 38/46 patients with at least 2 SNVs detected in plasma. As detailed in Extended 760 
Fig. 4c, 8/46 patients were not included in the analysis: CRUK0036 had no pre-op CT scan 761 
available, CRUK0087 had a large cavity inside the primary cancer, CRUK0099 had a collapsed 762 
lung making volume assessment inaccurate, CRUK0100, CRUK0077, CRUK0052 had a CT 763 
slice spacing of > 5 mm, and finally CRUK0088 and CRUK0091 had a total tumor volume < 764 
3.5 cm3. Linear regression was performed on log-transformed mean VAF and tumor volume. 765 
The log transformation was justified as it symmetrized the residuals in the model. An 766 
independent analysis was performed where tumor volume was multiplied with tumor purity to 767 
estimate the cancer cell volume. The same log transformation and analysis was applied to data 768 
acquired from Newman et al.16, where ctDNA VAF was determined based on CAPP-seq 769 
analysis with matched tumor volume data available. To analyze clone size versus ctDNA VAF 770 
for subclonal SNVs, the mean CCF of the mutations within a subclonal mutation cluster was 771 
multiplied with tumor volume, and as a second independent analysis, with tumor purity.  772 
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Extended Figure Legends 792 
Extended Data Figure 1. Multiplex-PCR next-generation sequencing platform analytical 793 
validation  794 
a) Analytical validation of the multiplex-PCR NGS platform was performed by spiking 795 
synthetic single nucleotide variants into control cell-free DNA. Sensitivity and specificity of 796 
the platform at different spike concentrations was ascertained, 95% binomial confidence 797 
interval displayed as error bars. b) Specificity of ctDNA detection based on a 1 SNV and 2 798 
SNV call threshold taking into account parallel testing of multiple SNVs. c) The median depth 799 
of read across a position did not vary depending on whether an SNV position was called or not 800 
called using the platform error-model. Wilcoxon Test, P=0.786, median depth of read at 801 
uncalled positions = 45,777 (n=3,745), range: 0 to 146774, median depth of read at called 802 
positions = 45,478, range= 1,354 to 152,974 (n=1,124). Whiskers represent 1.5 times the 803 
interquartile range, 2-sided test. 804 
 805 
Extended Data Figure 2. Study construction and assay-panel design  806 
a) The pre-operative study phase cohort consisted of 100 TRACERx patients present in the 807 
first 100 patient TRACERx cohort in April 2016. Pre-operative plasma samples were profiled 808 
in 96 patients for reasons listed. bi and ii) Contents of patient-specific assay-panels designed 809 
in the pre-operative study phase. c) The longitudinal study phase cohort consisted of patients 810 
with confirmed NSCLC relapse and patients without relapse. d) Contents of patient-specific 811 
assay-panels designed in the longitudinal phases of this study. e) Single nucleotide variant type 812 
targeted. 813 
 814 
Extended Data Figure 3 – Clinicopathological predictors of ctDNA detection  815 
a) 96 patients in pre-operative cohort stratified by pathological TNM stage. b) LUSCs and 816 
ctDNA positive LUADs are significantly more necrotic that ctDNA negative LUADs. 817 
Significant differences in necrosis between groups: LUSCs (median necrosis 40%) (n=31), 818 
ctDNA positive LUADs (median necrosis 15%) (n=11) and ctDNA negative LUADs (median 819 
necrosis 2%) (n=47), Kruskal-Wallis test, P<0.001, 2-sided pairwise comparisons were 820 
performed using Dunn’s procedure with Bonferroni correction. c) Univariate (left) and 821 
multivariate analyses (right) were performed, by logistic regression to determine significant 822 
predictors of ctDNA detection in early-stage NSCLC. ctDNA detection was defined as 823 
detection of two or more SNVs in pre-operative plasma samples. Details regarding 824 
multivariable analysis methodology are in methods. d) Receiver operating characteristic 825 
curve (ROC) analysis of pre-operative PET scan FDG-avidity (normalized as tumor 826 
background ratio (TBR), see methods), as a predictor of ctDNA detection (92/96 PET scans 827 
were available for central review). Median PET TBR of detected tumors = 9.01, n=45. 828 
Median PET TBR of undetected tumors= 3.64, n=47. P-value based on Wilcoxon Rank Sum 829 
Test. e) LUAD subtype analyses based on ctDNA detection and the presence of an EGFR, 830 
KRAS or TP53 driver mutation.  831 
 832 
Extended Data Figure 4. Predictors of plasma variant allele frequency  833 
a) Plasma variant allele frequencies of SNVs detected in plasma in 46 patients who were 834 
ctDNA positive (two or more SNVs detected). Clonal (blue) and subclonal (red) variant allele 835 
frequencies indicated, mean shown as horizontal line. Driver variants shown as triangles. b) 836 
Mean clonal VAF correlated with maximum tumor size measured in post-surgical specimen 837 
(pathological size, n=46) grey vertical bars represent range of clonal variant allele frequency. 838 
Shaded red background indicates 95% confidence interval. c) Filtering steps taken to define a 839 
group of ctDNA positive patients with volumetric data considered adequate to model tumor 840 
volume and plasma variant allele frequency. d) Scatter plot showing mean clonal VAF 841 
relative to tumor volume for TRACERx (blue dots and fitted blue line, n=38) and VAF 842 
relative to volume for previously published data based on CAPP-seq analysis of ctDNA 843 
(orange dots and orange fitted line, n=9). Orange shaded background indicates 95% 844 
confidence interval based on CAPP-seq data. e) Mean clonal VAF correlated with tumor 845 
volume × tumor purity (cancer cell volume), n=38. Shaded red background indicates 95% 846 
confidence interval. f) Association between number of cancer cells and VAF of clonal SNVs 847 
in plasma based on linear modelling of Extended Data Fig 4f. g) Detected subclonal SNVs 848 
were mapped back to M-Seq derived tumor phylogenetic trees (process illustrated in 849 
graphic). Detected private subclones (subclones identified within only a single tumor region) 850 
are coloured red. Shared subclones (subclones detected in more than one tumor regions) are 851 
light blue. Subclonal nodes were sized based on the maximum recorded cancer cell fraction 852 
(CCF). The top row of phylogenetic trees represent subclonal nodes targeted by primers 853 
within that patient’s assay panel, the bottom row represent subclonal nodes detected in 854 
ctDNA, within this row grey subclonal nodes represent subclones not detected in ctDNA.  855 
 856 
Extended Data Figure 5. Longitudinal ctDNA profiling, remaining relapse cases.  857 
a) Kaplan-Meier curve demonstrate relapse free survival for patients in whom ctDNA was 858 
detected versus patients in whom ctDNA was not detected. b-h) Longitudinal cell-free DNA 859 
profiling. Circulating tumor DNA (ctDNA) detection in plasma was defined as the detection 860 
of two tumor-specific SNVs. Relapse was based on imaging-confirmed NSCLC relapse, 861 
imaging performed as clinically indicated. Detected clonal (circles, light blue) and subclonal 862 
(triangles, colors indicates different subclones) SNVs from each patient-specific assay-panel 863 
are plotted on graphs colored by M-Seq derived tumor phylogenetic nodes. Mean clonal 864 
(blue) and mean subclonal (red) VAF are indicated on graphs. Pre-operative and relapse M-865 
Seq derived phylogenetic trees represented by ctDNA are illustrated above each graph in 866 
cases where subclonal SNVs were detected. 867 
 868 
Extended Data Figure 6. Longitudinal ctDNA profiling, non-relapse cases a-j) Detected 869 
clonal (circles, light blue) and subclonal (red triangles) SNVs from each patient-specific 870 
assay-panel are plotted on graphs. Mean clonal (blue) and mean subclonal (red) VAF are 871 
indicated on graphs.  872 
 873 
Extended Data Figure 7. Heatmaps illustrating detection of SNVs in bespoke panel at 874 
each sampled time point a, c-f) Bespoke assay panels for CRUK0063, CRUK0035, 875 
CRUK0044, CRUK0041 and CRUK0013. Colors indicate originating subclonal cluster based 876 
on the phylogenetic trees above the heatmap. Light blue indicates clonal mutation cluster. 877 
Full panel with cluster color shown below each heatmap. Filled squares indicates detection of 878 
a given variant in plasma ctDNA. Y-axis shows day of sampling, y-axis labels appended with 879 
[R] indicates day of clinical relapse. b) Re-examination of primary tumor regions from 880 
CRUK0063 with lowered threshold to potentially identify SNVs private to the sequenced 881 
relapse biopsy. 16/88 variants were found at very low VAF in region 3, indicating this region 882 
from the primary likely gave rise to the metastasis. 883 
 884 
Extended Data Figure 8. Heatmap illustrating detection of SNVs in bespoke panel based 885 
on M-seq of metastatic tumor regions for patient CRUK0063 for all sampled time 886 
points. Colors indicate originating subclonal cluster based on the phylogenetic trees above 887 
the heatmap. Light blue indicates clonal mutation cluster. Full panel with cluster color shown 888 
below each heatmap. Filled squares indicates detection of a given variant in plasma ctDNA. 889 
Y-axis shows day of sampling. 890 
 891 
Extended Table 1. Patient characteristics a) table of clinical characteristics describing the 892 
96 patient pre-operative cohort and b) demonstrating distribution of stage and whether the 893 
patient received adjuvant chemotherapy, c) demonstrating the time-points at which pre-894 
operative plasma was acquired for patients within the cohort, d) table of clinical characteristics 895 
describing 24 patient longitudinal cohort and e) demonstrating distribution of stage in the 896 
longitudinal cohort and whether the patient received adjuvant chemotherapy. 897 
 898 
Extended Table 2. Cross platform validation using a generic approach to ctDNA profiling 899 
a) 7/10 (70%) of bespoke-panel ctDNA positive patients had tumor SNVs detectable in plasma 900 
preoperatively by a generic hotspot PCR-NGS lung panel (Lung Oncomine, Thermofisher). 901 
The three bespoke-panel ctDNA positive patients undetected by the generic panel had mean 902 
clonal plasma variant allele frequencies lower than the 0.1% plasma variant allele frequency 903 
(VAF) limit of detection reported for the generic panel (shaded yellow). b) Based on CT 904 
volumetric assessment of each patient’s primary tumor we predicted plasma VAF 905 
corresponding to a tumor of that size (see Figure 3 and Methods for details of approach). This 906 
allowed us to infer platform sensitivities for each patient within the bespoke-panel non-detected 907 
cohort. Five LUADs (shaded green, CRUK0037, CRUK0051, CRUK0004, CRUK0039 and 908 
CRUK0025) had tumor volumes approximating to a plasma VAF of more than 0.1%. This 909 
suggested that these tumors resided within the top platform sensitivity bracket of both the 910 
generic and bespoke-panel ctDNA platforms. No ctDNA was detected by either platform in 911 
these cases, suggesting biological specificity of the bespoke-panel. c) Hotspot SNVs not 912 
identified in tumor tissue through exome sequencing were identified in plasma of 9 of 28 913 
patients by the generic panel. This suggested non-tumor origin of cell-free DNA, platform non-914 
specificity or an evolving minor subclone or second primary. 915 
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 Pre -operative  
assay -panels  
Longitudinal  
assay -panels  
Non -synonymous  1,547 542 
Stopgain  155 50 
Stop loss  1 10 
Synonymous  44 0 
Unknown  1 0 
Total  1,748 602 
SNV type 
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PET TBR ROC−curve
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d
c
TP53 driver
TotalNoYes
No
Yes
Total
2324 47
74 11
3028 58
ctDNA
detected
Fishers Exact Test P=0.508
LUAD
KRAS driver
TotalNoYes
Total
2720 47
83 11
3523 58
ctDNA
detected
EGFR driver
Total
Total
3611 47
101 11
4612 58
NoYes
ctDNA
detected No
Yes
No
Yes
Fishers Exact Test P=0.499
Fishers Exact Test P=0.429
Histological subtype
TNM Stage
TotalI II III
LUAD
No
Yes
LUSC
No
Yes
Other
No
Yes
34 7 6 47
5 2 4 11
1 0 0 1
16 12 2 30
2 0 0 2
1 2 2 5
ctDNA
detected
ctDNA
detected
ctDNA
detected
a
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100
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  LUAD
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P<0.001
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b
Predictors of ctDNA     detection    by multiplex-PCR NGS in early stage NSCLC 
 
 Univariable analysis Multivariable analysis 
                         
      OR (95% CI)                  P-value  
Clinicopathological variables   
 
Non-adenocarcinoma histology 
%Ki67+ cells (10% increase) 
Lympho-vascular invasion 
 Necrosis (10% increase)
 
 
  Male gender 
Age  (years)   
 Technical variables 
cfDNA input (ng) 
Ubiquitous SNVs in assay-panel 
<0.001 
<0.001 
0.028 
 <0.001
 
 0.172
 0.115
 
 
0.028 
0.341 
49.85 (12.93 -192.19) 
1.72  (1.40 - 2.12)
2.53  (1.10 - 5.80)   
 2.16  (1.58 - 2.97)
1.80  (0.78 - 4.16)
0.96  (0.92 - 1.01)
 
 
1.01 (1.00 - 1.03) 
0.96 (0.88 - 1.05) 
 
Ubiquitous SNVs (SNVs present in all tumour regions sequenced).  
Path tumour size (10mm increase)
OR (95% CI)                  P-value
40.76 (4.55 - 365.14)        0.001
1.40 (1.05 - 1.84)              0.022
5.84 (1.07 - 32.03)            0.042
1.04 (0.64 - 1.71)              0.862
3.82 (0.61 - 23.99)            0.153
0.134
1.06 (0.21-5.39)              0.941
0.99 (0.92-1.07)              0.820
 0.2291.01 (1.00 - 1.02) 
1.00 (0.84 - 1.19)               0.975 
Lymph-node involvement
1.32 (0.91-1.91)0.0041.45  (1.13 - 1.86)
0.0123.60  (1.33 - 9.77)
e
Mean subclonal VAFMean clonal VAFa c
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Other
Assay-panel targets SNVs
present in subclonal
nodes
SNVs detected in plasma 
mapped back to subclonal nodes
1 or more SNV present in private subclonal node detected
Clonal node
No SNVs in targeted subclonal node detected
Nodes sized based on subclone size
(max tumor region CCF)
Non-invasive representation of M-Seq derived NSCLC pylogenies
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One or more SNV
private to node 
detected in ctDNA
Multiplex-PCR NGS
1 or more SNV in shared subclonal node detected
Size
CRUK0034 CRUK0041
46 patients ctDNA positive (more than 2 SNVs detected)
45 patients CRUK0036 - no pre-op CT-scan available
43 patients
CRUK0087 – large cavity in tumor
CRUK0099 – collapsed lung
39 patients 3 patients with technically inadequate CT scan(CRUK0077 CRUK0052 CRUK0100)
38 patients CRUK0088 – inaccurate volumetric 
assessment due to tumor size 
Patients included in volumetric analysis
Volumetrics
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  Total 
Age <60 19 
 ≥60 77 
Sex Male  60 
 Female 36 
ECOG PS 0 49 
 1 47 
Histology Adenocarcinoma 58 
 Squamous cell 
carcinoma 31
 
 
Carcinosarcoma 2
 
 Large cell carcinoma 1 
 
Adenosquamous 
carcinoma
 
 
 
Large cell 
neuroendocrine 
 
 
 
1
 
TNM stage Ia 24 
 Ib 
 
35 
 IIa 12 
 IIb 11 
 IIIa  13 
 IIIb 1 
Lymph node 
metastasis 
Yes 24 
 No 72 
Pleural 
involvement 
Yes 27 
 No 69 
Vascular 
invasion 
Yes 41 
 No 55 
Resection 
margin 
R0 91 
 R1 5 
Smoking 
status 
Never smoked 11 
 Recent ex-smoker 30 
 Ex-smoker 48 
Ethnicity
   
   
   
   
 
Clinical characteristics 
96 patient  pre-operative cohort
Characteristic
  No adjuvant therapy Adjuvant therapy 
TNM Stage Ia 24 0 
 Ib 31 4 
 IIa 3 9 
 IIb 4 7 
 IIIa 6 7 
 IIIb 0 1 
a
b
Clinical characteristics 
24 patient  longitudinal sub-cohort
Extended Table 1 - Patient characteristic tables
  Total 
Age <60 5  
 ≥60 19 
Sex Male  16 
 Female 8  
ECOG PS 0 12 
 1 12 
Histology Adenocarcinoma 16 
 Squamous cell 
carcinoma 
8  
  
 
TNM stage Ia 3
 Ib 
 
7  
 IIa 3  
 IIb 7  
 IIIa  3 
 IIIb 1 
Lymph node 
metastasis 
Yes  
 No  
Pleural 
involvement 
Yes 7 
 No 17 
Vascular 
invasion 
Yes 12 
 No 12 
Resection 
margin 
R0 23 
 R1 1 
Smoking 
status 
Never smoked 1  
 Recent ex-smoker 5  
 Ex-smoker 16 
   
 21
  2
 Caribbean 1 
 
Characteristic
  No adjuvant therapy Adjuvant therapy 
TNM Stage Ia   
 Ib   
 IIa   
 IIb   
 IIIa   
 IIIb  
d
e
White-other
 
White BritishEthnicity
Current smoker 2   
 
White British 85
White-other 4
White-Irish 4
Caribbean 3
Current smoker 7
1
2
5
3
1
03
6
0
2
1
0
9
15
carcinoma
3
  Number  Details  
Less than 24 hours 91 
2  
  
  
c
 
Pre-surgery
24-72 hours
8 days
31 days
2
1
CRUK0073, 0096
CRUK0089
CRUK0051, 0003
Details regarding timing of pre-operative blood sample
 Targeted 
panel 
>99% sensivity at 0.1% VAF and above       
 
 
84% sensivity at 0.05% to 0.1% 
VAF         
 
 46 % sensivity 0.01% to 0.05% VAF         
 
 4.2% sensivity <0.01%         
 
         
 
Generic 
panel 90% sensivity at 0.1% VAF and above      
 
 
ND - non detected
DOR - depth of read
Combined exome VAF (unfiltered) - Variant allele frequency across all tumor regions analysed (without call filters).
Platform sensitivities predicted based on tumor volume
and analytical validation data in Extended Data 1
Oncomine lung panel sensitivity data reported at 
https://www.thermofisher.com/order/catalog/product/A31149
Multiplex-PCR NGS
Table 2 a - Bespoke panel detected NSCLCs - cross platform validation
Case Volume cm3 Plasma VAF (mean clonal) ctDNA posive Histology Hotspot SNVs tumor Hotspot SNVs detected
CRUK0029 38.51 2.10 Yes LUAD 1 1
CRUK0009 69.01 1.71 Yes LUAD 1 1
CRUK0062 58.48 1.41 Yes LUSC 1 1
CRUK0081 16.41 0.21 Yes LUSC 1 1
CRUK0089 17.39 0.16 Yes LUSC 1 1
CRUK0022 17.20 0.08 Yes LUAD 1 0
CRUK0067 6.64 0.07 Yes LUSC 1 0
CRUK0052 43.69 0.06 Yes LUAD 2 1
CRUK0064 9.24 0.05 Yes LUSC 1 0
CRUK0034 10.59 0.01 Yes LUAD 1 1
Table 2 b - Bespoke panel non-detected NSCLCs - cross platform validation
Case Volume cm3 Predicted plasma VAF ctDNA posive Histology Hotspot SNVs tumor Hotspot SNVs detected
CRUK0037 197.42 2.89 (0.93 - 8.97) No LUAD 1 0
CRUK0051 27.28 0.30 (0.19 to 0.46) No LUAD 1 0
CRUK0004 23.30 0.25 (0.16 to 0.38) No LUAD 1 0
CRUK0039 21.68 0.23 (0.15 to 0.35) No LUAD 2 0
CRUK0025 19.06 0.20 (0.13 to 0.30) No LUAD 2 0
CRUK0014 8.58 0.08 (0.04 to 0.15) No LUAD 1 0
CRUK0026 7.45 0.07 (0.04 to 0.13) No LUAD 1 0
CRUK0057 5.95 0.05 (0.02 to 0.11) No LUAD 1 0
CRUK0018 4.65 0.04 (0.02 to 0.09) No LUAD 1 0
CRUK0027 4.61 0.04 (0.02 to 0.09) No LUAD 1 0
CRUK0007 4.18 0.04 (0.01 to 0.08) No LUAD 1 0
CRUK0049 3.61 0.03 (0.01 to 0.08) No LUAD 1 0
CRUK0035 3.31 0.03 (0.01 to 0.07) No LUAD 1 0
CRUK0058 2.76 0.02 (0.01 to 0.06) No LUAD 1 0
CRUK0021 2.70 0.02 (0.01 to 0.06) No LUAD 2 0
CRUK0048 2.16 0.02 (0.01 to 0.05) No LUAD 2 0
CRUK0093 0.73 0.004 (0 to 0.03) No LUSC 2 0
CRUK0030 0.21 0.001 (0 to 0.01) No LUAD 2 0
(unfiltered) (unfiltered)
Case Gene Location Position Ref Variant AA change Plasma VAF DOR ctDNA positive Combined exome VAF Germline VAF 
CRUK0052 PIK3CA chr3 178936091 G A p.E545K 0.81 60360 Yes ND ND
CRUK0052 PIK3CA chr3 178952085 A G p.H1047R 0.12 52325 Yes 0.075 ND
CRUK0062 PIK3CA chr3 178936091 G A p.E545K 0.97 89616 Yes 0.016 ND
CRUK0062 PIK3CA chr3 178952085 A G p.H1047R 0.05 79205 Yes 0.005 ND
CRUK0062 TP53 chr17 7577556 C A p.C242F 0.05 93383 Yes ND ND
CRUK0089 TP53 chr17 7577121 G A p.R273C 0.06 59849 Yes 0.168 ND
CRUK0004 PIK3CA chr3 178936091 G A p.E545K 0.59 73941 No 0.081 ND
CRUK0018 PIK3CA chr3 178936091 G A p.E545K 4.44 99159 No ND ND
CRUK0018 PIK3CA chr3 178952085 A G p.H1047R 0.81 77806 No 0.044 ND
CRUK0021 PIK3CA chr3 178952085 A G p.H1047R 0.11 50107 No ND ND
CRUK0027 PIK3CA chr3 178952085 A G p.H1047R 0.11 65449 No ND ND
CRUK0037 PIK3CA chr3 178952085 A G p.H1047R 0.09 51071 No ND ND
CRUK0058 KRAS chr12 25398284 C A p.G12V 3.44 63090 No 0.124 ND
Table 2 c - Variants detected by generic PCR-NGS hotspot panel not detected in M-Seq analysis of tumor
Bespoke-panel
Bespoke-panel
Generic-panel
Generic-panel
